Overview of the drug development pipeline for pemphigus vulgaris
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and mucous membranes. The immune system makes antibodies to attack bacteria, virus, and other germs. In the people with pemphigus vulgaris, antibodies are produced against a protein that binds the skin cells together. As a result, the binding between many skin cells is broken, and this separates the cells from each other. Pemphigus vulgaris usually begins with mucous membranes, which are found in the mouth, throat, nose, and eyes. Owing to the several consequences of the disease and rising incidences of this medical condition, the need for the drug development for pemphigus vulgaris will increase considerably in the upcoming years.
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for pemphigus vulgaris. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of pemphigus vulgaris. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Almirall
- Immunomedics
- Novartis
- Principia Biopharma
Therapeutic assessment of the drug development pipeline for pemphigus vulgaris by route of administration
- Subcutaneous
- Intravenous
- Oral
The subcutaenous route of administration (ROA) involves the application of the drug directly into the layer of the skin below the dermis and the epidermis, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for pemphigus vulgaris by therapy
- Monotherapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for pemphigus vulgaris are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for pemphigus vulgaris?
- What are the companies that are currently involved in the development of drug molecules for pemphigus vulgaris?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.